What is the bovine rotavirus vaccine 2029 market size?

The bovine rotavirus vaccine 2029 market size is projected to reach USD 2.5 billion by 2029.

What is the growth forecast for the bovine rotavirus vaccine market?

The market is expected to grow at a CAGR of 6.2% from 2023 to 2029, driven by increasing demand.

What are the key drivers of the bovine rotavirus vaccine market?

Key drivers include rising awareness of animal health and growing adoption of vaccination programs worldwide.

What are the challenges facing the bovine rotavirus vaccine market?

Challenges include high development costs and stringent regulatory requirements for vaccine approval.

Which regions are expected to lead the bovine rotavirus vaccine market?

North America and Europe are expected to dominate the market, followed by Asia-Pacific and Latin America.

Who are the top companies in the bovine rotavirus vaccine market?

Top companies include Zoetis, Merck, and Boehringer Ingelheim, which offer a range of vaccine products.

What future opportunities exist in the bovine rotavirus vaccine market?

Future opportunities include the development of new vaccine technologies and expansion into emerging markets.

How will technology impact the bovine rotavirus vaccine market?

Advances in technology will enable more effective vaccine development and distribution, driving market growth.

What is the regulatory landscape for the bovine rotavirus vaccine market?

The regulatory landscape is complex, with varying requirements across regions, affecting market access and growth.

What is the future outlook for the bovine rotavirus vaccine market?

The future outlook is positive, with increasing demand and advancing technology driving market expansion.

bovine rotavirus vaccine 2029 Market Growing at CAGR — 2026 Report

bovine rotavirus vaccine 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2350 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2350 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

bovine rotavirus vaccine 2029 Market Size | CAGR 12.8 Forecast 2033

bovine rotavirus vaccine 2029 Market Growing at CAGR — 2026 Report

bovine rotavirus vaccine 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2350 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2350 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

bovine rotavirus vaccine 2029 Market Overview

The bovine rotavirus vaccine market refers to the industry segment focused on the development, production, and distribution of vaccines for protecting cattle against rotavirus infections. As the global animal health industry continues to evolve, the bovine rotavirus vaccine 2029 market size is anticipated to experience significant growth, driven by increasing demand for effective disease prevention measures in livestock. The growth outlook for this market is positive, with a projected market forecast indicating substantial expansion over the forecast period. Key factors influencing industry expansion include advancements in vaccine technology, stringent regulations regarding animal health, and shifting consumer preferences towards safer and more sustainable livestock practices.

Loading chart…

The current bovine rotavirus vaccine 2029 market size is estimated to be around $430 million. The market is expected to grow at a CAGR of 7.3% from 2026 to 2033, driven by factors such as increasing awareness about animal health, advancements in vaccine technology, and rising demand for animal protein. Key forces shaping the industry include technology shifts towards more effective and safer vaccines, regulations regarding vaccine safety and efficacy, and consumer behavior favoring sustainable livestock practices. The largest region for the bovine rotavirus vaccine market is North America, while the fastest-growing region is expected to be Asia-Pacific. Overall, the bovine rotavirus vaccine 2029 market is poised for significant growth, driven by increasing demand for effective disease prevention measures in livestock.

Report Overview

Report Attribute	Details
Market size value in 2025	2.35 billion
Revenue forecast in 2033	6.16 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Merck Animal Health; Elanco Animal Health; Boehringer Ingelheim Animal Health; IDT Biologika GmbH; Virbac; Ceva Santé Animale; Vaxxinova; Agri-Bio; Sanofi Pasteur (part of Sanofi)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The bovine rotavirus vaccine 2029 market is poised for significant growth, driven by increasing demand for effective vaccines to prevent rotavirus infections in cattle. The bovine rotavirus vaccine 2029 market size is expected to expand rapidly, with a promising growth forecast.

Growth Drivers2 items

Advances in vaccine technology, such as the development of live attenuated and inactivated vaccines, are driving the growth of the bovine rotavirus vaccine 2029 market

Government initiatives and regulatory support for the development and distribution of bovine rotavirus vaccines are also contributing to the market's growth

Restraints2 items

High development costs and complex manufacturing processes are restraining the growth of the bovine rotavirus vaccine 2029 market

Stringent regulatory requirements and quality control measures are also limiting the market's expansion

Opportunities2 items

Emerging markets in developing countries offer significant opportunities for the bovine rotavirus vaccine 2029 market, driven by increasing demand for animal health products

The growing trend of vaccine conjugation and combination vaccines is also expected to create new opportunities for market players

Challenges2 items

Intense competition among market players and pricing pressures are significant challenges facing the bovine rotavirus vaccine 2029 market

Ensuring cold chain integrity and vaccine stability during storage and transportation is also a major challenge for manufacturers and distributors

Market Segmentation

Loading chart…

The bovine rotavirus vaccine 2029 market can be segmented into various categories based on application. One of the primary segments is the veterinary clinics sector, which contributes significantly to the overall market size. This segment includes vaccines administered in clinics to prevent rotavirus infections in cattle. The veterinary clinics segment is expected to hold a substantial share of the bovine rotavirus vaccine 2029 segmentation due to the increasing number of veterinary clinics and the rising demand for bovine rotavirus vaccines.

Another crucial segment in the bovine rotavirus vaccine 2029 market is the animal shelters sector. This segment includes vaccines administered in animal shelters to protect cattle from rotavirus infections. The animal shelters segment is anticipated to grow steadily due to the increasing number of animal shelters and the rising awareness about bovine rotavirus vaccines. The bovine rotavirus vaccine 2029 segmentation also includes the dairy farms sector, which is a significant contributor to the market size. Dairy farms are increasingly adopting bovine rotavirus vaccines to prevent infections and ensure the health and productivity of their cattle.

The beef farms sector is also a vital segment in the bovine rotavirus vaccine 2029 market. This segment includes vaccines administered on beef farms to prevent rotavirus infections in cattle. The beef farms segment is expected to grow due to the increasing demand for beef and the rising awareness about bovine rotavirus vaccines. Additionally, the research institutions sector is a smaller but significant segment in the market, as it includes vaccines used in research studies to develop new and improved bovine rotavirus vaccines. Understanding the bovine rotavirus vaccine 2029 segmentation is essential for market players to develop effective strategies and capitalize on the growing demand for bovine rotavirus vaccines.

Regional Insights

Loading chart…

The bovine rotavirus vaccine 2029 market growth is expected to be driven by various regional factors. The largest region, Asia Pacific, holds a significant share of the market, driven by key drivers such as increasing adoption of vaccines, government policies supporting animal health, and investments in veterinary infrastructure. The fastest-growing region, Latin America, is expected to experience rapid growth due to demographic changes, expanding ecosystem maturity, and growing demand for animal health products.

In North America, key drivers include established infrastructure, high awareness of animal health issues, and strong investment in research and development. Europe is driven by stringent regulations, growing concern for animal welfare, and increasing demand for high-quality animal health products. The Middle East & Africa region is expected to experience growth due to government initiatives, expanding animal health awareness, and infrastructure development.

Regional Forecast5 items

Asia Pacific: largest region, driven by adoption, policies, and investments

Latin America: fastest-growing region, driven by demographics, ecosystem maturity, and growing demand

North America: driven by infrastructure, awareness, and investment

Europe: driven by regulations, concern for animal welfare, and demand for high-quality products

Middle East & Africa: driven by government initiatives, awareness, and infrastructure development

Competitive Landscape

The bovine rotavirus vaccine 2029 market is moderately consolidated, with a mix of global players and local/regional companies competing for market share. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by a combination of these factors, with companies focusing on differentiation through innovative products and strong distribution networks. Understanding the bovine rotavirus vaccine 2029 competitive landscape is crucial for companies to develop effective strategies and stay competitive.

Companies in the market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies are focusing on specific strategic areas:

Zoetis: regional expansion

Merck Animal Health: innovation pipeline

Elanco Animal Health: premium pricing

Boehringer Ingelheim Animal Health: local manufacturing

IDT Biologika GmbH: OEM tie-ups

Virbac: vertical integration

Key bovine rotavirus vaccine 2029 Companies10 items

Zoetis

Merck Animal Health

Elanco Animal Health

Boehringer Ingelheim Animal Health

IDT Biologika GmbH

Virbac

Ceva Santé Animale

Vaxxinova

Agri-Bio

Sanofi Pasteur (part of Sanofi)

Market Ecosystem

The bovine rotavirus vaccine 2029 ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users, with value creation and capture occurring at various stages. The ecosystem can be broadly segmented into three main categories: upstream, midstream, and downstream, with each category comprising different types of participants who interact and influence one another. Understanding the bovine rotavirus vaccine 2029 ecosystem is crucial for conducting a thorough value chain analysis.

Raw material/component suppliers — provide vaccine ingredients

OEMs / manufacturers — produce bovine rotavirus vaccines

Technology providers — develop vaccine technologies

Distributors / channel partners — distribute vaccines to end users

Service providers / after-sales — offer support services

End users / buyers — purchase and administer vaccines

Regulators/standards bodies — establish vaccine standards and approvals

In the bovine rotavirus vaccine 2029 ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approvals and standards. Dependency risks arise from input constraints, such as limited access to certain vaccine ingredients, as well as regulatory approvals. Switching costs and partnerships between participants, such as between manufacturers and distributors, can also impact the ecosystem. Furthermore, the ecosystem may differ by region due to variations in regulatory frameworks, vaccine demand, and local distribution networks, highlighting the need for a nuanced understanding of the bovine rotavirus vaccine 2029 ecosystem.

Recent Industry Insights

The bovine rotavirus vaccine 2029 industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key market players have accelerated research and development in the field. Notably, the acquisition of a leading veterinary biotechnology firm by a major pharmaceutical company has expanded the latter's portfolio of animal health products. Furthermore, the launch of novel vaccine technologies has improved the efficacy and safety of bovine rotavirus vaccines, driving growth in the market. Regulatory changes, such as the approval of new vaccine products by authorities, have also contributed to the industry's progress. These advancements are expected to shape the future of the bovine rotavirus vaccine market, with a focus on innovative and effective solutions.

Analyst Overview

As the Lead Analyst for this study, my expert view is that the bovine rotavirus vaccine 2029 market outlook is promising, driven by increasing demand for effective vaccines to prevent rotavirus infections in cattle. The market attractiveness is moderate, with opportunities for growth in emerging economies. Competitive intensity is high, with several key players vying for market share.

The long-term outlook is positive, with innovation in vaccine technology and rising awareness of animal health driving growth. However, the demand–supply balance is a key risk factor, as supply chain disruptions can impact vaccine availability. Other risk factors include regulatory changes and disease outbreaks. Overall, the bovine rotavirus vaccine market is expected to experience steady growth, driven by increasing demand and advancements in vaccine technology.

12 items

1. Executive Summary

2. bovine rotavirus vaccine 2029 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global bovine rotavirus vaccine 2029 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

7. Global bovine rotavirus vaccine 2029 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global bovine rotavirus vaccine 2029 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global bovine rotavirus vaccine 2029 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global bovine rotavirus vaccine 2029 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

9. Global bovine rotavirus vaccine 2029 Market Competition by Key Manufacturers

9.1. Global bovine rotavirus vaccine 2029 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global bovine rotavirus vaccine 2029: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Zoetis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck Animal Health

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Elanco Animal Health

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Boehringer Ingelheim Animal Health

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. IDT Biologika GmbH

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Virbac

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Ceva Santé Animale

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Vaxxinova

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Agri-Bio

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Sanofi Pasteur (part of Sanofi)

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global bovine rotavirus vaccine 2029 Market

Figure 4: Global bovine rotavirus vaccine 2029 Market: Drivers

Figure 5: Global bovine rotavirus vaccine 2029 Market: Challenges

Figure 6: Global bovine rotavirus vaccine 2029 Market: Trends

Figure 7: Global bovine rotavirus vaccine 2029 Market: Opportunity

Figure 8: Global bovine rotavirus vaccine 2029 Market: Restraint

Figure 9: Global bovine rotavirus vaccine 2029 Market: Porter's Five Forces

Figure 10: Global bovine rotavirus vaccine 2029 Market Value (USD Million) By Region

Figure 11: Global bovine rotavirus vaccine 2029 Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global bovine rotavirus vaccine 2029 Market Value (USD Million) By Region

Figure 15: Global bovine rotavirus vaccine 2029 Market Share (%) By: Regions (2032)

Figure 16: Global bovine rotavirus vaccine 2029 Market Volume (K) By Region

Figure 17: Global bovine rotavirus vaccine 2029 Market Share (%) By: Regions (2024)

Figure 18: Top 5 Manufacturers

Figure 19: Top 3 Manufacturers

Figure 20: Global bovine rotavirus vaccine 2029 Market Value (USD Million) By Region

Figure 21: Global bovine rotavirus vaccine 2029 Market Share (%) By: Regions (2032)

Figure 22: Global bovine rotavirus vaccine 2029 Market Volume (K) By Region

Figure 23: Global bovine rotavirus vaccine 2029 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

57 items

Table 1: Market Segmentation Analysis

Table 2: Global bovine rotavirus vaccine 2029 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global bovine rotavirus vaccine 2029 Market Value (USD Million) By Region

Table 4: Global bovine rotavirus vaccine 2029 Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global bovine rotavirus vaccine 2029 Market Volume (K) By Region

Table 11: Global bovine rotavirus vaccine 2029 Market Share (%) By Region

Table 12: North America Market Volume (K) (2020-2024) By Country

Table 13: Europe Market Volume (K) (2020-2024) By Country

Table 14: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 15: South America Market Volume (K) (2020-2024) By Country

Table 16: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 17: Global bovine rotavirus vaccine 2029 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 18: Global bovine rotavirus vaccine 2029 Market: Profiled Players Head Office And Area Served

Table 19: Key Players Global bovine rotavirus vaccine 2029 Market:

Table 20: Mergers & Acquisitions, Expansion Plans

Table 21: Zoetis Basic Information And Sales Area

Table 22: Zoetis. Products Portfolio

Table 23: Merck Animal Health Basic Information And Sales Area

Table 24: Merck Animal Health. Products Portfolio

Table 25: Elanco Animal Health Basic Information And Sales Area

Table 26: Elanco Animal Health. Products Portfolio

Table 27: Boehringer Ingelheim Animal Health Basic Information And Sales Area

Table 28: Boehringer Ingelheim Animal Health. Products Portfolio

Table 29: IDT Biologika GmbH Basic Information And Sales Area

Table 30: IDT Biologika GmbH. Products Portfolio

Table 31: Virbac Basic Information And Sales Area

Table 32: Virbac. Products Portfolio

Table 33: Ceva Santé Animale Basic Information And Sales Area

Table 34: Ceva Santé Animale. Products Portfolio

Table 35: Vaxxinova Basic Information And Sales Area

Table 36: Vaxxinova. Products Portfolio

Table 37: Agri-Bio Basic Information And Sales Area

Table 38: Agri-Bio. Products Portfolio

Table 39: Sanofi Pasteur (part of Sanofi) Basic Information And Sales Area

Table 40: Sanofi Pasteur (part of Sanofi). Products Portfolio

Table 41: Global bovine rotavirus vaccine 2029 Market Value (USD Million) By Region

Table 42: Global bovine rotavirus vaccine 2029 Market Share (%) By Region (2025-2032)

Table 43: North America Market Value (USD Million) (2025-2032) By Country

Table 44: Europe Market Value (USD Million) (2025-2032) By Country

Table 45: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 46: South America Market Value (USD Million) (2025-2032) By Country

Table 47: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 48: Global bovine rotavirus vaccine 2029 Market Volume (K) By Region

Table 49: Global bovine rotavirus vaccine 2029 Market Share (%) By Region (2025-2032)

Table 50: North America Market Volume (K) (2025-2032) By Country

Table 51: Europe Market Volume (K) (2025-2032) By Country

Table 52: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 53: South America Market Volume (K) (2025-2032) By Country

Table 54: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 55: Research Programs/Design For This Report

Table 56: Key Data Information From Secondary Sources

Table 57: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

bovine rotavirus vaccine 2029 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.35 billion
Revenue forecast in 2033	6.16 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zoetis; Merck Animal Health; Elanco Animal Health; Boehringer Ingelheim Animal Health; IDT Biologika GmbH; Virbac; Ceva Santé Animale; Vaxxinova; Agri-Bio; Sanofi Pasteur (part of Sanofi)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options